PCH
ZBIO

Polar Capital Holdings’s Zenas BioPharma ZBIO Stock Holding History

Polar Capital Holdings’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.8M Buy
2,548,444
+1,490,835
+141% +$33.5M 0.18% 96
2025
Q4 		$38.4M Buy
+1,057,609
New +$34.8M 0.15% 114

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Polar Capital Holdings's ZBIO Position: Q1 2026 in Review

Polar Capital Holdings increased its Zenas BioPharma (ZBIO) stake by 141% in Q1 2026, buying an estimated $33.5M and bringing the position to 2,548,444 shares worth $49.8M. The position accounts for 0.18% of the portfolio, ranked #96.

Polar Capital Holdings first reported a position in ZBIO in Q4 2025 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Polar Capital Holdings held 2,548,444 shares of Zenas BioPharma worth $49.8M as of Q1 2026.
  • Polar Capital Holdings bought 1,490,835 Zenas BioPharma shares in Q1 2026, an estimated $33.5M.
  • Zenas BioPharma made up 0.18% of Polar Capital Holdings's portfolio in Q1 2026, its #96 holding.
  • Polar Capital Holdings first reported a position in Zenas BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.